Back to top
more

Celyad (CYAD)

(Real Time Quote from BATS)

$0.47 USD

0.47
NA

0.00 (0.00%)

Updated May 18, 2023 08:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

5 Beaten-Down Biotech Bets to Bounce Back in 2022

by Indrajit Bandyopadhyay

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer

by Zacks Equity Research

Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.

Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate

by Zacks Equity Research

Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.

Sreoshi Bera headshot

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

by Sreoshi Bera

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

All You Need to Know About Celyad SA (CYAD) Rating Upgrade to Strong Buy

by Zacks Equity Research

Celyad SA (CYAD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Top Ranked Momentum Stocks to Buy for April 20th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th

What Makes Celyad SA (CYAD) a New Buy Stock

by Zacks Equity Research

Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Celyad SA (CYAD) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Celyad SA (CYAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Celyad Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Celyad has been struggling lately, but the selling pressure may be coming to an end soon.

Celyad SA Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Celyad has been struggling lately, but the selling pressure may be coming to an end soon.

Celyad Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Celyad has been struggling lately, but the selling pressure may be coming to an end soon.

Celyad (CYAD) Jumps: Stock Rises 6.8%

by Zacks Equity Research

Celyad (CYAD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

    Arpita Dutt headshot

    3 Biotech Stocks That More than Doubled Year to Date

    by Arpita Dutt

    Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.